Dr. Li Wang 王丽
Chief Physician
Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Standardized comprehensive treatment for lung cancer, breast cancer, and gastrointestinal tumors.
Dr. Li Wang is a Chief Physician with a Master of Medicine. Since 1995, Dr. Wang has worked in the Department of Medical Oncology at Jiangsu Cancer Hospital. Dr. Wang manages common tumors and related complications and participates in multi-center clinical trials for new anti-tumor drugs.
Name order: in Chinese the family name comes first (Wang Li). Papers usually list the name as Li Wang or Wang L.
Selected publications
34 papers on PubMed matched by name and affiliation; 6 as first or senior author since 2016. Most recent first- or senior-author papers:
- BMC Cancer, 2026 (first author): Improving prediction accuracy of radiation-induced temporal lobe injury in nasopharyngeal carcinoma using ADC-based deep learning and dosiomics. PubMed 41652361
- Signal Transduct Target Ther, 2024 (senior author): Benmelstobart plus anlotinib in patients with EGFR-positive advanced NSCLC after failure of EGFR TKIs therapy: a phase I/II study. PubMed 39389963
- Head Neck, 2024 (first author): A pretreatment multiparametric MRI-based radiomics-clinical machine learning model for predicting radiation-induced temporal lobe injury in patients with nasopharyngeal carcinoma. PubMed 38887926
- Lung Cancer (Auckl), 2023 (first author): Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib. PubMed 37842288
- Front Pharmacol, 2021 (first author): Comparison of Improvement in 2-Year Survival Rate of Patients with Stage II-III Non-Small Cell Lung Cancer Treated with Different Durations of Chinese Patent Medicine: A Retrospective Cohort Study. PubMed 34539404
- Mol Med Rep, 2021 (first author): [Retracted] Regulation of the cell cycle and PI3K/Akt/mTOR signaling pathway by tanshinone I in human breast cancer cell lines. PubMed 33846794
- Mol Med Rep, 2015 (first author): Regulation of the cell cycle and PI3K/Akt/mTOR signaling pathway by tanshinone I in human breast cancer cell lines. PubMed 25355053
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion